| Primary immune deficiency disorder
Xembify vs Cutaquig
Side-by-side clinical, coverage, and cost comparison for primary immune deficiency disorder.Deep comparison between: Xembify vs Cutaquig with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsCutaquig has a higher rate of injection site reactions vs Xembify based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Cutaquig but not Xembify, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Xembify
Cutaquig
At A Glance
SC injection
Daily to every 2 weeks
Immune globulin replacement
SC injection
Weekly
Immune globulin (IGSC)
Indications
- Primary immune deficiency disorder
- Congenital agammaglobulinemia
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Primary immune deficiency disorder
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Congenital agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
Dosing
Primary immune deficiency disorder, Congenital agammaglobulinemia, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency SC infusion only; treatment-naive: 150 mg/kg/day loading dose for 5 consecutive days, then 150 mg/kg/week maintenance starting Day 8; switching from IVIG: begin 1 week after last IVIG, initial weekly dose (g) = prior IVIG dose (g) x 1.37 / number of weeks between IVIG doses; switching from IGSC: administer same weekly dose (g) as prior IGSC; doses may be adjusted for frequent (2-7 times/week) or biweekly administration.
Primary immune deficiency disorder, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Congenital agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency Individualized SC dose based on pharmacokinetic and clinical response; for patients switching from IGIV, calculate initial weekly dose by dividing monthly IGIV dose by weeks between infusions and multiplying by adjustment factor of 1.30; for patients switching from IGSC, maintain same weekly dose; dosing interval from daily up to every other week.
Contraindications
- Previous anaphylactic or severe systemic reaction to human immune globulin
- IgA deficiency with antibodies against IgA and history of hypersensitivity to human immune globulin treatment
- Previous anaphylactic or severe systemic reaction to subcutaneous administration of human immune globulin or to any component of CUTAQUIG, including Polysorbate 80
- IgA deficiency with antibodies against IgA and history of hypersensitivity to human globulin treatment
Adverse Reactions
Most common (>=5%) Infusion site erythema, infusion site pain, infusion site swelling, infusion site bruising, infusion site nodule, infusion site pruritus, infusion site induration, infusion site scab, infusion site edema, cough, diarrhea
Postmarketing Anaphylactic reaction, hypersensitivity, aseptic meningitis, dizziness, paresthesia, tachycardia, hypotension, dyspnea, chest discomfort, injection site reactions, chills, fatigue, pain, tremor, laryngospasm
Most common (>=5%) Local infusion site reactions (redness, swelling, itching), headache, fever, dermatitis, asthma, diarrhea, cough
Postmarketing Pancytopenia, leukopenia, hemolytic anemia, anaphylactic reaction, hypersensitivity reaction, angioneurotic edema, thromboembolism, Stevens-Johnson syndrome, aseptic meningitis, seizures, cardiac arrest, respiratory failure, pulmonary embolism, acute renal failure, dizziness, nausea, pruritus, fatigue
Pharmacology
XEMBIFY supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against bacterial, viral, parasitic, and mycoplasmal agents and their toxins, and contains antibodies capable of interacting with and altering the activity of immune system cells, though the full mechanism is not completely understood.
Immune globulin replacement; CUTAQUIG supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against bacterial and viral agents, with IgG subclass distribution closely proportional to native human plasma, restoring abnormally low IgG levels to the normal range to help prevent infections in primary humoral immunodeficiency.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Xembify
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
Cutaquig
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (6/12) · Qty limit (0/12)
UnitedHealthcare
Xembify
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Cutaquig
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (1/8) · Qty limit (1/8)
Humana
Xembify
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (0/3)
Cutaquig
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Primary Immune Deficiency - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/fillfill
Octapharma IgCares Co-Pay Assistance Program: CutaquigCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
XembifyView full Xembify profile
CutaquigView full Cutaquig profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.